What's in Veru Inc.'s pipeline?

Veru Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Veru Inc.'s portfolio?

No competitive overlap detected.

Subscribe to /feed/company/veru-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Veru Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area	First approval
Enzalutamide, Abiraterone	Enzalutamide, Abiraterone	phase 3	Androgen receptor antagonist + CYP17A1 inhibitor combination	Androgen receptor (AR) and CYP17A1	Oncology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for Veru Inc.:

Drug Landscape (2026). Veru Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/veru-inc. Accessed 2026-05-15.